The Incidence and Management of Cutaneous Adverse Events of the Epidermal Growth Factor Receptor Inhibitors
January 2017
in “
Postępy Dermatologii i Alergologii
”
TLDR EGFR inhibitors can cause various skin issues during cancer treatment, and managing these is important for patient care.
The document discussed the overexpression of the epidermal growth factor receptor (EGFR) in various cancers and the use of EGFR inhibitors in their treatment. It highlighted that skin lesions during cancer treatment could result from various factors, including specific drugs and therapies. The exact mechanism of skin toxicity from EGFR inhibitors was not well understood but was linked to the modification of the RAS/RAF/MEK/ERK signaling pathway. Common side effects included pruritus, xerosis, papulopustular rash, hand-foot skin reaction, alopecia, hair dystrophy, and paronychia. The document provided options for preventing and managing these adverse events, which are crucial for patient care during oncological treatment.
